Stockhub

Sonnet BioTherapeutics Holdings, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

14 August 2022

31 July 2022

  • curprev 07:2707:27, 31 July 2022‎ 172.18.0.2 talk‎ 924 bytes +924‎ Created page with "Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Sonnet_BioTherapeutics_Holdings,_Inc.’